Aytu BioPharma Statistics

Total Valuation

Aytu BioPharma has a market cap or net worth of GBP 15.68 million. The enterprise value is 18.86 million.

Market Cap	15.68M
Enterprise Value	18.86M

Important Dates

The next estimated earnings date is Friday, September 26, 2025.

Earnings Date	Sep 26, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	6.17M
Shares Outstanding	n/a
Shares Change (YoY)	+52.64%
Shares Change (QoQ)	-3.31%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	6.66M

Valuation Ratios

The trailing PE ratio is 12.36.

PE Ratio	12.36
Forward PE	n/a
PS Ratio	0.25
PB Ratio	0.58
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 3.34, with an EV/FCF ratio of -4.25.

EV / Earnings	14.87
EV / Sales	0.32
EV / EBITDA	3.34
EV / EBIT	n/a
EV / FCF	-4.25

Financial Position

The company has a current ratio of 1.03, with a Debt / Equity ratio of 0.65.

Current Ratio	1.03
Quick Ratio	0.76
Debt / Equity	0.65
Debt / EBITDA	2.92
Debt / FCF	-3.92
Interest Coverage	-0.30

Financial Efficiency

Return on equity (ROE) is -3.06% and return on invested capital (ROIC) is -1.39%.

Return on Equity (ROE)	-3.06%
Return on Assets (ROA)	-0.59%
Return on Invested Capital (ROIC)	-1.39%
Return on Capital Employed (ROCE)	-2.22%
Revenue Per Employee	619,640
Profits Per Employee	12,437
Employee Count	102
Asset Turnover	0.65
Inventory Turnover	2.37

Taxes

In the past 12 months, Aytu BioPharma has paid 361,453 in taxes.

Income Tax	361,453
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -34.72% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-34.72%
50-Day Moving Average	1.61
200-Day Moving Average	2.41
Relative Strength Index (RSI)	71.86
Average Volume (20 Days)	2,207

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	0.44

Income Statement

In the last 12 months, Aytu BioPharma had revenue of GBP 63.20 million and earned 1.27 million in profits.

Revenue	63.20M
Gross Profit	40.94M
Operating Income	-919,500
Pretax Income	-415,633
Net Income	1.27M
EBITDA	4.64M
EBIT	-919,500
Earnings Per Share (EPS)	-0.64

Full Income Statement

Balance Sheet

The company has 14.07 million in cash and 17.43 million in debt, giving a net cash position of -3.37 million.

Cash & Cash Equivalents	14.07M
Total Debt	17.43M
Net Cash	-3.37M
Net Cash Per Share	n/a
Equity (Book Value)	27.01M
Book Value Per Share	4.38
Working Capital	1.40M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -4.28 million and capital expenditures -163,312, giving a free cash flow of -4.44 million.

Operating Cash Flow	-4.28M
Capital Expenditures	-163,312
Free Cash Flow	-4.44M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 64.77%, with operating and profit margins of -1.45% and 2.01%.

Gross Margin	64.77%
Operating Margin	-1.45%
Pretax Margin	-0.66%
Profit Margin	2.01%
EBITDA Margin	7.35%
EBIT Margin	-1.45%
FCF Margin	n/a

Dividends & Yields

Aytu BioPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-52.64%
Shareholder Yield	n/a
Earnings Yield	8.09%
FCF Yield	-28.33%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on January 6, 2023. It was a reverse split with a ratio of 0.05.

Last Split Date	Jan 6, 2023
Split Type	Reverse
Split Ratio	0.05

Scores

Aytu BioPharma has an Altman Z-Score of -2.8 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.8
Piotroski F-Score	3